Literature DB >> 7585505

The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus.

M Hollyoake1, A Stühler, P Farrell, J Gordon, A Sinclair.   

Abstract

B lymphocytes in the peripheral circulation are maintained in a non-proliferative state. Antigen recognition stimulates limited proliferation, whereas infection with Epstein-Barr virus (EBV) results in continual proliferation and the outgrowth of immortal cell lines. Because it is not clear at which point in cell cycle the peripheral B lymphocytes are arrested, we characterized the expression of several cell cycle-associated genes in quiescent and stimulated cells. We show that the expression of four cell genes, cdc-2, cyclin E, CD23, and cyclin D2, are up-regulated approximately 100-fold as a result of EBV-mediated immortalization. Because these genes play a positive role in cell proliferation, we suggest that this regulatory switch contributes to controlling entry into the cell cycle. Transient stimulation of quiescent B lymphocytes with either a cocktail of anti-CD40, anti-IgM, and IL4, or EBV results in the rapid expression of the same four genes, suggesting that, after infection, EBV exploits the normal program of B-lymphocyte cell cycle activation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585505

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  The murine gammaherpesvirus 68 v-cyclin gene is an oncogene that promotes cell cycle progression in primary lymphocytes.

Authors:  L F van Dyk; J L Hess; J D Katz; M Jacoby; S H Speck; I V Virgin HW
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus.

Authors:  L C Spender; E J Cannell; M Hollyoake; B Wensing; J M Gawn; M Brimmell; G Packham; P J Farrell
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 3.  Strategies in subversion: de-regulation of the mammalian cell cycle by viral gene products.

Authors:  C Swanton; N Jones
Journal:  Int J Exp Pathol       Date:  2001-02       Impact factor: 1.925

4.  Characterization of ABF-1, a novel basic helix-loop-helix transcription factor expressed in activated B lymphocytes.

Authors:  M E Massari; R R Rivera; J R Voland; M W Quong; T M Breit; J J van Dongen; O de Smit; C Murre
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

5.  Characterization and cell cycle regulation of the major Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent genes and their promoter.

Authors:  R Sarid; J S Wiezorek; P S Moore; Y Chang
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity.

Authors:  W Chen; N R Cooper
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  The murine gammaherpesvirus 68 v-cyclin is a critical regulator of reactivation from latency.

Authors:  L F van Dyk; H W Virgin; S H Speck
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection.

Authors:  L C Spender; G H Cornish; B Rowland; B Kempkes; P J Farrell
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

9.  Variability of gene expression profiles in human blood and lymphoblastoid cell lines.

Authors:  Josine L Min; Amy Barrett; Tim Watts; Fredrik H Pettersson; Helen E Lockstone; Cecilia M Lindgren; Jennifer M Taylor; Maxine Allen; Krina T Zondervan; Mark I McCarthy
Journal:  BMC Genomics       Date:  2010-02-08       Impact factor: 3.969

10.  EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases.

Authors:  Hem Chandra Jha; Jie Lu; Abhik Saha; Qiliang Cai; Shuvomoy Banerjee; Mahadesh A J Prasad; Erle S Robertson
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.